Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Invivyd filed an 8-K on 6/14. No major details yet, but keep an eye out.
AI Summary
Invivyd, Inc. filed an 8-K on June 14, 2024, to report other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA. This filing does not contain specific financial figures or details about the 'other events'.
Why It Matters
This 8-K filing indicates that Invivyd, Inc. has made a regulatory submission, which could signal significant corporate or financial developments that investors should monitor.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and financial statements, lacking specific material disclosures that would immediately impact risk.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Name
- June 14, 2024 (date) — Report Date
- Waltham, MA (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Invivyd, Inc. in this 8-K filing?
The provided text for the 8-K filing does not specify the details of the 'Other Events' beyond listing it as an item information category.
When was Invivyd, Inc. formerly known as Adagio Therapeutics, Inc.?
The date of the name change from Adagio Therapeutics, Inc. to Invivyd, Inc. was November 12, 2020.
What is the principal executive office address for Invivyd, Inc.?
The principal executive offices of Invivyd, Inc. are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the Commission File Number for Invivyd, Inc.?
The Commission File Number for Invivyd, Inc. is 001-40703.
What is the SIC code for Invivyd, Inc.?
The Standard Industrial Classification (SIC) code for Invivyd, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 9.9 · Accepted 2024-06-14 07:07:19
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20240614.htm (8-K) — 49KB
- ivvd-ex99_1.htm (EX-99.1) — 20KB
- img59752938_0.jpg (GRAPHIC) — 84KB
- 0000950170-24-073322.txt ( ) — 312KB
- ivvd-20240614.xsd (EX-101.SCH) — 31KB
- ivvd-20240614_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On June 14, 2024, Invivyd, Inc. issued a press release entitled "Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated June 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: June 14, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary